Choose Your Country or Region

PD-1/PD-L1

Choose Selective PD-1/PD-L1 Inhibitors

Isoform-selective Inhibitors

PD-1/PD-L1 Products

All (15)
PD-1/PD-L1 Inhibitors (14)
PD-1/PD-L1 Agonist (1)
New PD-1/PD-L1 Products

Catalog No.	Product Name	Information	Product Use Citations
A2002	Nivolumab (anti-PD-1)	Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Cell, 2022, 185(9):1521-1538.e18 Mol Cancer, 2022, 21(1):20 Mol Ther, 2022, S1525-0016(22)00088-0
A2004	Atezolizumab (anti-PD-L1)	Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Cell, 2022, 185(9):1521-1538.e18 Mol Cancer, 2022, 21(1):60 Sci Adv, 2021, 7(6)eaba0776
A2005	Pembrolizumab (anti-PD-1)	Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	Immunity, 2022, 55(3):512-526.e9 Cancer Lett, 2022, 531:39-56 Int J Radiat Oncol Biol Phys, 2022, S0360-3016(22)00143-2
A2013	Durvalumab (anti-PD-L1)	Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.	J Med Chem, 2022, 65(5):3879-3893 Mol Pharm, 2022, 10.1021/acs.molpharmaceut.2c00084 J Med Chem, 2021, 64(15):11614-11636
A2016	Camrelizumab (anti-PD-1)	Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
A2017	Spartalizumab (anti-PD-1)	Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.	Elife, 2020, 9
A2035^New	Sintilimab (anti-PD-1)	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
S7911	BMS-1 (PD-1/PD-L1 inhibitor 1)	BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.	ChemMedChem, 2021, 16(3):568-577 J Cancer Res Clin Oncol, 2021, 10.1007/s00432-021-03694-4 Neoplasia, 2021, 23(3):281-293
S7912	BMS202 (PD-1/PD-L1 inhibitor 2)	BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.	Cancer Lett, 2021, 522:238-254 Adv Healthc Mater, 2021, e2101496 Front Pharmacol, 2021, 12:671611
S8158	PD-1/PD-L1 Inhibitor 3	PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM	Biochem Pharmacol, 2022, 197:114940 ChemMedChem, 2022, e202200091 Nat Chem, 2021, 10.1038/s41557-021-00829-5
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Med Chem, 2022, 10.1021/acs.jmedchem.1c01941 Fundam Clin Pharmacol, 2022, 10.1111/fcp.12759 J Clin Invest, 2021, 140752
S8549	AUNP-12	AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.	Carcinogenesis, 2022, bgac043 Molecules, 2019, 24(15)
S8859	BMS-1166	BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.	Biomaterials, 2022, 282:121407
S9610	BMS-1001	BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
A2002	Nivolumab (anti-PD-1)	Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Cell, 2022, 185(9):1521-1538.e18 Mol Cancer, 2022, 21(1):20 Mol Ther, 2022, S1525-0016(22)00088-0
A2004	Atezolizumab (anti-PD-L1)	Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Cell, 2022, 185(9):1521-1538.e18 Mol Cancer, 2022, 21(1):60 Sci Adv, 2021, 7(6)eaba0776
A2005	Pembrolizumab (anti-PD-1)	Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	Immunity, 2022, 55(3):512-526.e9 Cancer Lett, 2022, 531:39-56 Int J Radiat Oncol Biol Phys, 2022, S0360-3016(22)00143-2
A2013	Durvalumab (anti-PD-L1)	Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.	J Med Chem, 2022, 65(5):3879-3893 Mol Pharm, 2022, 10.1021/acs.molpharmaceut.2c00084 J Med Chem, 2021, 64(15):11614-11636
A2016	Camrelizumab (anti-PD-1)	Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
A2017	Spartalizumab (anti-PD-1)	Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.	Elife, 2020, 9
A2035^New	Sintilimab (anti-PD-1)	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
S7911	BMS-1 (PD-1/PD-L1 inhibitor 1)	BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.	ChemMedChem, 2021, 16(3):568-577 J Cancer Res Clin Oncol, 2021, 10.1007/s00432-021-03694-4 Neoplasia, 2021, 23(3):281-293
S7912	BMS202 (PD-1/PD-L1 inhibitor 2)	BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.	Cancer Lett, 2021, 522:238-254 Adv Healthc Mater, 2021, e2101496 Front Pharmacol, 2021, 12:671611
S8158	PD-1/PD-L1 Inhibitor 3	PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM	Biochem Pharmacol, 2022, 197:114940 ChemMedChem, 2022, e202200091 Nat Chem, 2021, 10.1038/s41557-021-00829-5
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Med Chem, 2022, 10.1021/acs.jmedchem.1c01941 Fundam Clin Pharmacol, 2022, 10.1111/fcp.12759 J Clin Invest, 2021, 140752
S8549	AUNP-12	AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.	Carcinogenesis, 2022, bgac043 Molecules, 2019, 24(15)
S8859	BMS-1166	BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.	Biomaterials, 2022, 282:121407
S9610	BMS-1001	BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
A2035^New	Sintilimab (anti-PD-1)	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.